ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 2560 • 2019 ACR/ARP Annual Meeting

    Factors Associated with Hydroxychloroquine Use in Systemic Lupus Erythematosus Patients with End Stage Renal Disease

    Maria Salgado Guerrero1, Alejandra Londono Jimenez 2, Chrisanna Dobrowolsky 2, Shudan Wang 2, Wenzhu B. Mowrey 3 and Anna Broder 2, 1Internal Medicine, Jacobi Medical Center/Albert Einstein College of Medicine, Bronx, NY, 2Rheumatology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY, 3Albert Einstein College of Medicine, Bronx, NY

    Background/Purpose: Hydroxychloroquine (HCQ) use in SLE has been associated with a lower risk of end-organ damage, SLE flares, and thrombosis1,2. However the benefits of HCQ…
  • Abstract Number: 2561 • 2019 ACR/ARP Annual Meeting

    Deep Remission During Induction Therapy for Lupus Nephritis Prevents Damage Accrual and Associates with the Baseline Proportions of Peripheral Treg, CD8+ T Cells, and NKT-like Cells

    Jun Kikuchi1, Hironari Hanaoka 1, Shuntaro Saito 1, Tatsuhiro Oshige 1, Kazuoto Hiramoto 1, Yuko Kaneko 1, Noriyasu Seki 2, Hideto Tsujimoto 2 and Tsutomu Takeuchi 1, 1Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, 2Mitsubishi Tanabe Pharma Corporation Sohyaku. Innovative Research Division, Toda-shi, Saitama, Japan

    Background/Purpose: chievement of renal remission has been the target of the induction therapy in patients with active lupus nephritis (LN). Deep remission (DR) defined as…
  • Abstract Number: 2562 • 2019 ACR/ARP Annual Meeting

    Glucocorticosteroid Usage and Major Organ Damage in Patients with Systemic Lupus Erythematosus – Meta-analyses of Observational Studies Published Between 1979 and 2018

    Anselm Mak1, Mike W.L.- Cheung 1, Wai Yee Joanna Leong 2, Bhushan Dharmadhikari 3, Nien Yee Kow 3, Michelle Petri 4, Susan Manzi 5, Ann Clarke 6, Cynthia Aranow 7, Laurent Arnaud 8, Anca Askanase 9, Sang-Cheol Bae 10, Sasha Bernatsky 11, Ian Bruce 12, Jill Buyon 13, W. Winn Chatham 14, Nathalie Costedoat-Chalumeau 15, MA Dooley 16, Paul Fortin 17, Ellen M Ginzler 18, Dafna Gladman 19, Caroline Gordon 20, John G Hanly 21, Murat Inanc 22, David A Isenberg 23, Soren Jacobsen 24, Judith James 25, Andreas Jönsen 26, Kenneth C Kalunian 27, Diane Kamen 28, S Sam Lim 29, Eric Morand 30, Christine Peschken 31, Bernardo A. Pons-Estel 32, Anisur Rahman 33, Rosalind Ramsey-Goldman 34, Juanita Romero-Diaz 35, Guillermo Ruiz-Irastorza 36, Jorge Sanchez-Guerrero 37, Kristjan Steinsson 38, Elisabet Svenungsson 39, Murray Urowitz 40, Ronald van Vollenhoven 41, Evelyne Vinet 42, Alexandre Voskuyl 43, Daniel J Wallace 44 and Graciela Alarcón 45, 1National University of Singapore, Singapore, Singapore, 2Changi General Hospital, Singapore, Singapore, 3National University of Singapore, Singapore, 4Johns Hopkins University School of Medicine, Baltimore, MD, 5Allegheny Health Network, Pittsburg, PA, 6University of Calgary, Calgary, AB, Canada, 7Feinstein Institute for Medical Research, Manhasset, NY, 8Service de Rhumatologie, Centre National de Référence des Maladies Autoimmunes Systemiques Rares (RESO), Hôpitaux Universitaires de Strasbourg, Strasbourg, France, Strasbourg, France, 9Columbia University Medical Center, New York, NY, 10Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, 11Research Institute of the McGill University Health Centre, Montreal, QC, Canada, 12University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom, 13NYU School of Medicine, New York, 14University of Alabama Medical Center, Birmingham, AL, 15Cochin University Hospital, Paris, France, 16UnC Kidney Centre, Chapel Hill, NC, 17Division de Rhumatologie, Département de Médecine, CHU de Québec – Université Laval, Axe maladies infectieuses et inflammatoires, Centre de recherche du CHU de Québec – Université Laval, Canada, Quebec, QC, Canada, 18State University of New York Downstate Medical Center, Brooklyn, NY, 19Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, 20University of Birmingham, Birmingham, United Kingdom, 21Dalhousie University, Halifax, NS, Canada, 22Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, 23Centre for Rheumatology, London, United Kingdom, 24Copenhagen Lupus and Vasculitis Clinic, Copenhagen, Denmark, 25Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 26Lund University, Lund, Sweden, 27UC San Diego School of Medicine, LaJolla, CA, 28Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA., Charleston, SC, 29Emory University, Atlanta, GA, 30Monash University, Melbourne, Victoria, Australia, 31University of Manitoba, Winnipeg, Canada, 32Centro Regional de Enfermedades Autoinmunes y Reumáticas (CREAR), Grupo Oroño, Rosario, Rosario, Argentina, 33University College London, London, United Kingdom, 34Northwestern University, Chicago, IL, 35Instituto Nacional de Ciencias Medicas y Nutricion Salvador, Zubiran Vasco de Quiroga, Mexico City, Mexico, 36Autoimmune Diseases Unit, Hospital Universitario Cruces, Barakaldo, Spain, Barakaldo, Spain, 37Toronto Western Hospital, Toronto, ON, Canada, 38Landspitali, University Hospital, Reykjavik, Iceland, 39Division of Rheumatology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, 40University Health Network, University of Toronto, Toronto, ON, Canada, 41Amsterdam Rheumatology and Immunology Center ARC, Amsterdam, the Netherlands, Amsterdam, Netherlands, 42McGill University Health Centre, Montreal, QC, Canada, 43Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, 44Cedars-Sinai Medical Centre, Beverly Hills, CA, 45University of Alabama at Birmingham, Birmingham

    Background/Purpose: The impact of glucocorticoid (GC) use on major organ damage in SLE patients has not been formally studied by amalgamating the relevant data published…
  • Abstract Number: 2563 • 2019 ACR/ARP Annual Meeting

    PK/PD, Safety and Exploratory Efficacy of Subcutaneous Anifrolumab in SLE: A Phase-II Study in Interferon Type I High Patients with Active Skin Disease

    Ian Bruce1, Alireza Nami 2, Erik Schwetje 3, M Edward Pierson 4, Yen Lin Chia 5, Denison Kuruvilla 5, Gabriel Abreu 6, Raj Tummala 3 and Catharina Lindholm 6, 1University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom, 2Joint & Muscle Medical Care, Charlotte, NC, US, Charlotte, NC, 3AstraZeneca, Gaithersburg, MD, USA, Gaithersburg, MD, 4AstraZeneca, Gaithersburg, MD, US, Gaithersburg, MD, 5AstraZeneca, South San Francisco, CA, US, South San Francisco, CA, 6AstraZeneca, Gothenburg, Sweden, Gothenburg, Sweden

    Background/Purpose: Anifrolumab, a fully human anti–IFN Type I receptor mAb, is under investigation for the treatment of SLE at a dose of 300 mg intravenously…
  • Abstract Number: 2564 • 2019 ACR/ARP Annual Meeting

    Adherence to Hydroxychloroquine Influences the Incidence of Organ Damage During Follow-up in Patients with Systemic Lupus Erythematosus

    Ji-Hyoun Kang1, Seong-Eun Choi 1, Haimuzi Xu 1, Dong-Jin Park 1 and Shin-Seok Lee 2, 1Chonnam National University Medical School & Hospital, Gwangju, Republic of Korea, 2Department of Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, Republic of Korea

    Background/Purpose: Hydroxychloroquine (HCQ) is a cornerstone drug in patients with systemic lupus erythematosus (SLE), decreasing the risk of flares and comorbidities and improving survival. This…
  • Abstract Number: 2565 • 2019 ACR/ARP Annual Meeting

    Pharmacokinetics and Exposure-response of Intravenous Belimumab in Children with Systemic Lupus Erythematosus

    Richard Dimelow 1, Beulah Ji2 and Herbert Struemper 3, 1GSK, Stevenage, United Kingdom, 2GSK, Uxbridge, Middlesex, United Kingdom, 3GSK, Research Triangle Park

    Background/Purpose: Belimumab is approved in adults with active SLE and for childhood-onset SLE (cSLE). PLUTO, a Phase 2, placebo-controlled, double-blind trial (114055; NCT01649765), was the first…
  • Abstract Number: 2566 • 2019 ACR/ARP Annual Meeting

    Polypharmacy and Potentially Inappropriate Medication Use in Young versus Older Adults with SLE

    Dale Seguin1, Christine Peschken 2, Casandra Dolovich 1, Ruby Grymonpre 1, Phil St. John 1 and Annaliese Tisseverasinghe 1, 1University of Manitoba, Winnipeg, MB, Canada, 2University of Manitoba, Winnipeg, Canada

    Background/Purpose: Polypharmacy, typically defined as ≥ 5 medications (meds),  is a strong risk factor for adverse clinical outcomes, including delirium, falls, hospitalization, and death, especially…
  • Abstract Number: 2567 • 2019 ACR/ARP Annual Meeting

    Prospective Evaluation of American Academy of Ophthalmology Low Dose Hydroxychloroquine Recommendation in Stable Lupus Nephritis with High-Risk Retinopathy: Lipid Profile and Flare Rates

    Tatiana Pedrosa 1, Sandra G. Pasoto 1, Emily Yuki2, Nadia Aikawa 1, Eduardo Borba 1, Julio Ferreira Filho 1, Pedro Carricondo 3, Caio Zanetti 1, Paola Conde 1, Nicole Fontoura 1, Paschoalina Romano 4, Valdemir Carvalho 5, Clovis Silva 6 and Eloisa Bonfa 7, 1Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Brazil, 2Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., São Paulo, Brazil, 3Ophtalmology Division, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Brazil, 4Division of Central Laboratory, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Brazil, 5Fleury Group, Sao Paulo, Brazil, Sao Paulo, Brazil, 6Pediatric Rheumatology Unit, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Brazil, 7Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Sao Paulo, Brazil

    Background/Purpose: Hydroxychloroquine (HCQ) is the most well established therapy for SLE, as it provides several beneficial properties, such as favorable effects on lipid profile, reduced…
  • Abstract Number: 2568 • 2019 ACR/ARP Annual Meeting

    Iguratimod Is an Alternative Option for Refractory Lupus Nephritis: A Preliminary Observational Study

    Qingran Yan1, Chunde Bao 2, Yuening Kang 1, Qiong Fu 1 and Ran Wang 1, 1Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of medicine, Shanghai, China (People's Republic), 2Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of medicine, Shanghai, Shanghai, China (People's Republic)

    Background/Purpose: Despite significant advances in the management of patients with lupus nephritis (LN), a significant proportion of patients either do not respond to first-line immunosuppressive…
  • Abstract Number: 2569 • 2019 ACR/ARP Annual Meeting

    Guidelines on Prescribing and Monitoring Antimalarials in Rheumatic Diseases: A Systematic Review

    Gemma Cramarossa1, Janet Pope 2 and Matthew Turk 3, 1Schulich School of Medicine & Dentistry, University of Western Ontario, London, ON, Canada, 2Western University, London, ON, Canada, 3University of Western Ontario, London, ON, Canada

    Background/Purpose: The purpose of this systematic review was to identify existing guidelines for antimalarial prescribing and monitoring in rheumatic diseases, specifically for hydroxychloroquine, and how…
  • Abstract Number: 2570 • 2019 ACR/ARP Annual Meeting

    Urinary Cellular Profile as a Biomarker for Proliferative Lupus Nephritis

    Amira El Gerby 1, Abeer Abdelati 2, Hanaa Donia 3 and Nouran Eshak4, 1Rheumatology Department, Faculty of Medicine, Alexandria University, Egypt, Alexandria, Egypt, 2alexandria university, alexandria, Egypt, 3Clnical and Chemical Pathology Department, Faculty of Medicine, ALexandria University, Alexandria, Egypt, 4Rheumatology Unit, Internal Medicine Department, Faculty of Medicine, Alexandria University, Lubbock, TX

    Background/Purpose: Proliferative lupus nephritis (LN) is one of the most common and serious manifestations of SLE and is a major cause of morbidity. A search…
  • Abstract Number: 2571 • 2019 ACR/ARP Annual Meeting

    Early Improvement in SLEDAI-2K Responder Index-50 Predicts SRI-4 Response in a Randomized Placebo-Controlled Trial of Ustekinumab (UST) in Systemic Lupus Erythematosus

    Zahi Touma1, Dafna Gladman 2, Shawn Rose 3, Kaiyin Fei 3, Yun Gregan 3, Robert Gordon 3, Kim Hung Lo 3 and Murray Urowitz 1, 1University Health Network, University of Toronto, Toronto, ON, Canada, 2Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, 3Janssen Research & Development, LLC, Spring House, PA

    Background/Purpose: While traditional Systemic Lupus Erythematosus (SLE) Disease Activity Index 2000 (SLEDAI-2K) scoring assesses complete SLE response for individual disease manifestations, the SLEDAI-2K Responder Index-50…
  • Abstract Number: 2572 • 2019 ACR/ARP Annual Meeting

    Efficacy Analysis of Patients with Systemic Lupus Erythematosus Treated with Belimumab or Placebo Plus Standard Therapy in Phase 3 Trials by Baseline Levels of BLyS mRNA and Type 1 Interferon Inducible Gene Signature Status

    Angela R Jones-Leone1, Shaun Flint 2, Roger Abramino Levy 3, David Roth 4, Robert Henderson 2, Christel Wilkinson 2, Beulah Ji 5 and Damon L Bass 3, 1GlaxoSmithKline, Upper Providence, 2GlaxoSmithKline, Stevenage, United Kingdom, 3GlaxoSmithKline, Collegeville, PA, 4GSK, Collegeville, PA, 5GSK, Uxbridge, Middlesex, United Kingdom

    Background/Purpose: Belimumab (BEL) is a B-lymphocyte stimulator (BLyS) inhibitor approved as an add-on to standard of care (SoC) for patients with autoantibody-positive SLE with active…
  • Abstract Number: 2573 • 2019 ACR/ARP Annual Meeting

    Hydroxychloroquine Levels in Patients with Systemic Lupus Erythematosus: Comparison of Whole Blood and Serum Levels

    Benoit Blanchet 1, Jallouli Moez 2, Marie Allard 3, veronique le guern 4, Jean-Charles Piette 5, Noémie Jourde-Chiche 6 and Nathalie Costedoat-Chalumeau7, 1Cochin, Paris, France, 2sfax, SFAX, Tunisia, 3Hôpital Bichat Claude-Bernard, Paris, France, 4APHP, paris, France, 5Hôpital Pitié-Salpêtrière, Paris, France, 6APHM, Marseille, Marseille, France, 7Cochin University Hospital, Paris, France

    Background/Purpose: Hydroxychloroquine (HCQ) levels can be measured in whole blood as well as in serum but both methods have never been compared. Cut offs for…
  • Abstract Number: 2574 • 2019 ACR/ARP Annual Meeting

    Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effect of BIIB059, a Monoclonal Antibody Targeting BDCA2 Following Administration of Subcutaneous Single Doses in Japanese Healthy Volunters

    Cristina Musselli1, Francois Gaudreault 1, Naik Himanshu 1, Hua Carroll 1, Ankur Sharma 1, Xiaobi Huang 1 and Nathalie Franchimont 1, 1Biogen, Cambridge, MA

    Background/Purpose: Background: BDCA2 is a plasmacytoid dendritic cell (pDC)-specific receptor that, when ligated inhibits the production of inflammatory mediators and Type I Interferon (INF), a…
  • « Previous Page
  • 1
  • …
  • 927
  • 928
  • 929
  • 930
  • 931
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology